Join FCAAP and Integrity CE for the October Atopic Dermatitis Pediatric State Society Series Meeting

Topic: The Critical Role of Pediatric Clinicians in Achieving Best Practices in Atopic Dermatitis Assessment, Management, and Referral

Date: Thursday, October 28, 2021

Time: 12:30-2:00 PM Eastern Time (US and Canada)

Speaker: Stanley M. Fineman, MD, Pediatric Allergist at Atlanta Allergy & Asthma Clinic

Program Overview

Atopic dermatitis (AD) is a chronic relapsing and remitting inflammatory skin disease that affects 7.2% of adults and 12% of children. Disability and a poor quality of life (QOL) are associated with AD, particularly among patients who are suboptimally managed. Pediatricians and primary care providers (PCPs) are often the first point-of-contact for patients with AD. Data from 1996-1999 compared to 2012-2015 found that PCP visits for children and adults with AD increased 300%, yet dermatologist visits for AD decreased 17%. In children, pediatricians were the most frequently sought provider for AD.

Although PCPs and pediatricians are seeing an increase in AD cases, recent evidence shows these clinicians are lacking in their ability to accurately diagnose and assess disease severity. In a recent survey, only 29% of PCPs were able to recognize essential features and characteristic distribution of AD to support diagnosis. Another survey found a discrepancy between how physicians and patients rate AD severity, with patients focusing more on skin-related QOL outcomes and physicians focusing more on sleep disturbance. In pooled data from prior Integrity CE programs on AD targeting PCPs and pediatricians, only 46% of participants selected to assess itch, sleep, and daily life vs objective measures to determine AD severity at baseline. Early-onset AD, which develops within the first 2 years of life, occurs in 60% of children with AD. While as many as 2 out of 3 of these children will experience remission before age 11, recurrences in adolescence and early adulthood are common. Many moderate-to-severe cases of AD in adulthood often begin as early-onset disease that was suboptimally treated or miscategorized. Education to ensure clinicians are prepared to effectively diagnose and assess disease severity is therefore necessary. This series will address these educational gaps among PCPs and pediatricians, and application of the knowledge gained will improve outcomes for patients with AD.

Target Audience

This educational initiative has been designed for primary care physicians, pediatricians, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals.

Learning Objectives

• Integrate evidence-based diagnostic criteria and assessment strategies into the routine identification and evaluation of children and adults with known or suspected AD
• Apply current guideline recommendations to the effective management of children and adults with AD
• Review safety and efficacy data on new and emerging therapies for children and adults with AD
• Demonstrate prompt referral of patients with AD to specialist care in accordance with guideline
  recommendations and best practices

Integrity Continuing Education, Inc. designates this activity for a maximum of 1.5 AMA PRA Category 1
Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation
in the activity. Review full accreditation details.

Click here to RSVP for the event.